article thumbnail

Ginkgo Bioworks and Vivici Partner to Revolutionize Alternative Dairy Protein Production

XTalks

In a significant move towards revolutionizing the alternative dairy protein market, cell programming and biosecurity platform Ginkgo Bioworks has joined forces with Vivici BV , an innovative business-to-business (B2B) ingredients startup. This process ensures optimal protein expression and functionality at a commercial scale.

Protein 105
article thumbnail

Dyadic expands Covid-19 licence with Rubic to bolster vaccine production in Africa

Pharmaceutical Technology

Dyadic International has announced expansion of a licence agreement for its C1-cell protein expression platform with South African consortium Rubic One Health. The expanded licence will include the development of vaccines and therapeutic proteins beyond Covid-19 for human and animal health markets in Africa.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Host-Cell Protein Analytics: History and Future Trends

Pharmaceutical Technology

The ability to detect host-cell proteins in bioprocessing streams is a vital tool in pharmaceutical firms' product purification arsenal

Protein 130
article thumbnail

Astellas and Cullgen to develop small molecule protein degraders

Pharmaceutical Technology

Japan-based Astellas Pharma has entered a partnership with Cullgen to discover and develop multiple targeted protein degraders through the latter’s proprietary uSMITE targeted protein degradation platform, in a deal potentially worth $1.9bn. This method can target enzymes, transcription factors, scaffold proteins and more.

Protein 130
article thumbnail

Key Parkinson’s protein could offer new potential targets for treatment

Pharma Times

Researchers from Johns Hopkins University School of Medicine have revealed new findings about a key pathological protein associated with Parkinson’s disease (PD), which could lead to new treatments. Estimated to affect over 8.5 However, its relation to dopaminergic neuron death is unclear.

Protein 96
article thumbnail

Gilead Sciences to exclusively license Nurix Therapeutics’ protein degrader

Pharmaceutical Technology

Gilead Sciences has exercised its option to exclusively license the investigational targeted protein degrader development candidate, NX‑0479, from clinical-stage biopharmaceutical company Nurix Therapeutics. Additionally, Nurix will receive up to low double-digit tiered royalties on the net sales of the product.

Protein 130
article thumbnail

Univar Solutions to Expand ICL’s Plant-Based Protein Offerings

XTalks

Univar Solutions , a leading global distributor of ingredients and chemicals, has recently been chosen to distribute ICL’s Rovitaris line of textured plant proteins in North America. The company prides itself on its relentless drive to continually develop and refine products that fill existing gaps in the market.

Protein 98